Conclusion
Extended-release PEO tablets of the practically water insoluble drug gliclazide (30 mg) and freely soluble metformin HCl (500
mg) retained their hydrated structural integrity when exposed to 5% and 40% w/v ethanol solutions for up to 12 h. The matrices
did not fail in hydro-alcoholic media. Small differences in drug release profiles were explained in terms of drug solubility
in various media. The results of this study identified trends similar to those in previously published data for HPMC ER matrix
systems.
Exposure of compacts of three different viscosity grades of PEO (Polyox 1105, 301, and Coagulant) to water or hydro-alcoholic
solutions had shown gradual swelling and gelation without any disruption to the tablet integrity. The compact wet weight appeared
to be only slightly lower in hydro-alcoholic solutions compared to water. The extent of their relative swelling was found
to increase with increasing molecular weight of PEO from 900,000 Da to 5,000,000 Da. No significant difference in compact
relative swelling was observed when MW increased further from 4,000,000 Da (Polyox 301) to 5,000,000 Da (Polyox Coagulant).
This study clearly indicates that PEO matrices produces consistent drug release in water and in hydro-alcoholic media with
no signs of a potential dose dumping.
Marina Levina, PhD,* is senior manager, product development at Colorcon Limited, mlevina@colorcon.com
, +44 (1) 322-627321. Dasha Palmer is product development scientist, Thomas P. Farrell, PhD, is director, product development, and Ali R. Rajabi-Siahboomi, PhD, is director of scientific affairs, all at Colorcon in Dartford, England.
*To whom all correspondence should be addressed.
Submitted: Feb. 17, 2011. Accepted: Apr. 5, 2011.
References
1. M. Levina and A.R. Rajabi-Siahboomi, J. Pharm. Sci.
93 (11) 2746–2754 (2004).
2. S.U. Choi, J. Lee, and Y.W. Choi, Drug. Dev. Ind. Pharm.
29 (10) 1045–1052 (2003).
3. H. Li, R.J. Hardy, and X. Gu, AAPS. PharmSci.
9 (2) 437–443 (2008).
4. R.L. Davidson, Handbook of Water-Soluble Gums and Resins (McGraw-Hill, New York, NY, 1980).
5. N.B. Graham and M.E. McNeil, Biomaterials.
5 (1) 27–36 (1984).
6. A. Apicella et al., Biomaterials. 14 (2) 83–91 (1993).
7. J.W. Moore and H.H. Flanner, Pharm. Technol.
20 (6) 64–74 (1996).
8. L. Yang, G. Venkatesh, and R. Fassihi, J. Pharm. Sci.
85 (10) 1085–1090 (1996).
9 F. Zhang and J.W. McGinity, Pharm. Dev. Technol. 4 (2) 241–250 (1999).
10. A.M. Razaghi and J.B. Schwartz, Drug. Dev. Ind. Pharm.
28 (6) 695–701 (2002).
11. S. Dhawan, M. Varma, and V.R. Sinha, Pharm. Technol.
29 (5) 72–79 (2005).
12. S. Dhawan, K. Dhawan and V.R. Sinha, Pharm. Technol.
29 (5) 82–96 (2005).
13. M. Levina, A. Gothoskar, and A.R. Rajabi-Siahboomi, Pharm. Technol. Eur.
18 (7) 20–26 (2006).
14. Handbook of Pharmaceutical Excipients, 3rd ed., R.C. Rowe, P.J. Sheskey, and M.E. Quinn, Eds. (Pharmaceutical Press, London, 2009).
15. L. Maggi, R. Bruni, and U. Conte, Int. J. Pharm.
195 (1-2) 229–238 (2000).
16. J. Siepmann and N.A. Peppas, Adv. Drug. Deliv. Rev.
48 (2–3) 139–157 (2001).
17. M. Levina, D. Palmer, and A.R. Rajabi-Siahboomi, Drug. Del. Tech.
10 (5) 18–23 (2010).
18. M. Levina, H. Vuong, and A.R Rajabi-Siahboomi, Drug. Dev. Ind. Pharm.
33 () 1125–1134 (2007).
19. National Health Service, "Statistics on Alcohol: England" (NHS, UK, 2009),
http://www.ic.nhs.uk/pubs/alcohol09/, accessed Sept. 2010.
20. M.K. Serdula et al., Am. J. Prev. Med.
26 (4) 294–298 (2004).
21. W. Roth et al., Int. J. Pharm.
368 (1-2) 72–75 (2009).
22. B. Skalsky et al., presentation at the 34th Annual Meeting and Exposition of the Controlled Release Society (Long Beach,
CA, 2007).
23. A. Makin and R. William, Q. J. Med.
93 (6) 341–349 (2000).
24. FDA, "FDA ALERT [7/2005]: Alcohol-Palladone Interaction,"
http://www.fda.gov/ (Rockville, MD, 2005).
25. H.M. Fadda, Y. AlBasarah, and A. Basit, presentation at the AAPS Annual Meeting and Exposition (San Antonio, TX, 2006).
|
